Germany's Springer Nature Journal Publication on TruScreen

NZX/ASX Announcement 11 November 2024 Report published by leading research journal, Germany’s Springer Nature concluded that TruScreen cervical cancer screening results were comparable and even better (for patients with type 3 TZ) than conventional LBC (Liquid based Cytology) Highlights • Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation zone (TZ) types • A cohort of 1,908 women aged 34.0±7.3 years who have received cytology (LBC), human papillomavirus (HPV) testing, TruScreen, and colposcopy were evaluated • TruScreen detection accuracy was comparable to liquid-based cytology (LBC and performs even better in patients with type 3 TZ TruScreen Group Limited (NZX/ASX: TRU) is pleased to advise the publication of “Evaluation of a real-time optoelectronic method for the detection of cervical intraepithelial neoplasia and cervical cancer in patients with different transformation zone types” conducted by Dr Fengyi Xiao & Professor Long Sui from The Cervical Diseases Centre, Obstetrics and Gynaecology Hospital of Fudan University, Shanghai, China. The study evaluated the diagnostic value of TruScreen, a real-time diagnostic technology, for cervical lesions in patients with different transformation zone (TZ) types. Full report can be downloaded from the below link. https://www.nature.com/articles/s41598-024-78773-w The Obstetrics and Gynaecology Hospital of Fudan University study concluded that TruScreen optoelectronic real time screening detection accuracy was comparable to liquid-based cytology (LBC) and outperformed in patients with type 3 TZ. The publication of the Fudan University’s study results reiterated the COGA (Chinese Obstetricians and Gynaecologists Association) large scale clinical trial of 15,661 patients conducted across 9 China Provinces over 3 years, that determined TruScreen to be a simple, effective and rapid real-time method to screen for cervical cancer. The COGA trial results highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-HPV co-testing (see NZX/ASX announcement 05 April 2022 ). The Fudan University patient cohort have received cytology, human papillomavirus (HPV) testing, TruScreen, and colposcopy. The clinical performances of these tests were evaluated for their detection of high-grade squamous intraepithelial lesion (HSIL), adenocarcinoma in situ (AIS), or more severe lesions in patients with different TZ types. The results of the study found: • TruScreen's sensitivity (65.08%) was higher to that for LBC (57.14%), • TruScreen’s specificity (64.76%) was similar to that of LBC (64.47%). For patients with type 3 TZ, TruScreen results outperformed LBC • TruScreen's sensitivity (72.29%) was higher to that for LBC (65.06%), • TruScreen’s specificity (67.39%) was higher to that of LBC (64.29%). Martin Dillon, CEO said: “The Fudan University study by Dr Fengyi Xiao and Professor Long Sui affirms the TruScreen AI enabled optoelectronic cervical cancer screening technology. As member nations of the World Health Organisation embrace the WHO’s objective of eliminating cervical cancer by the end of the century, TruScreen real time screening technology is a vital medical device to support the global task of achieving WHO’s strategy. The TruScreen real time technology does not require expensive pathology infrastructure and is the screening technology of choice for countries with regional areas with limited access to pathology laboratory testing infrastructure and qualified clinicians to interpret the results.” “TruScreen is approved and on the national cervical cancer screening guidelines of China and Russia, and on the national Technical List of Vietnam’s MoH and Cofepris of Mexico for use in the public health sector. Several countries are currently evaluating TruScreen for inclusion into its national screening guidelines.” This announcement was approved for release by the Board. -ENDS- For more information, visit www.truscreen.com or contact: Marty Dillion Chief Executive Officer martindillon@truscreen.com Guy Robertson Chief Financial Officer guyrobertson@truscreen.com